Compare Microchip Technology Inc. (MCHP) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs Summit Therapeutics Inc — how do they compare? Microchip Technology Inc. trades at $74.37 (market cap $41.01B), while Summit Therapeutics Inc trades at $17.45 (market cap $13.71B). The key difference: Microchip Technology Inc. is far larger — about 3× Summit Therapeutics Inc's market cap, and Microchip Technology Inc. pays a 2.41% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Microchip Technology Inc. for 62 Days and Summit Therapeutics Inc for 16 Days on average.
| MCHP | SMMT | |
|---|---|---|
Market Cap | $41.01B | $13.71B |
Volume | 9,972,516 | 6,173,057 |
Sector | Technology | Health |
52-Week High | $102.97 | $26.38 |
52-Week Low | $49.02 | $12.43 |
Typical Hold Time | 62 Days | 16 Days |
Enterprise Value | $46.13B | $13.04B |
Dividend Yield | 2.41% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microchip Technology (MCHP) trades at $74.00, down 5.15% over 24 hours amid a bearish technical signal. The company reported a net loss of -$500,000 in 2025, a sharp decline from prior profitability, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion in Ethernet and 48V power portfolios and the completion of the Hailo acquisition, targeting growth in automotive, industrial, and AI-driven data center markets.
Outlook: Strong analyst consensus (69.57% Buy) and a $110.50 price target suggest significant upside potential, driven by AI infrastructure demand and portfolio expansion. Key risks include high valuation multiples, substantial long-term debt of $5.63B, and sensitivity to semiconductor cycle volatility. Earnings recovery in 2026 forecasts is critical for sustaining investor confidence.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
